MIRM — Mirum Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1759425 ·
Last close
$122.13
Market Cap
$7.45B
52W High
$130.00
52W Low
$88.34
ADV30
971,464
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 159,882,000 | 131,077,000 | -63,163,000 | -790,155,000 | 890,916,000 | 324,907,000 | 648,422,000 |
| Dec 2025 | 148,932,000 | 120,668,000 | -4,567,000 | -5,730,000 | 842,813,000 | 296,683,000 | 528,123,000 |
| Sep 2025 | 133,010,000 | 107,473,000 | 2,603,000 | 2,905,000 | 785,115,000 | 282,021,000 | 493,069,000 |
| Jun 2025 | 127,785,000 | 104,364,000 | -4,989,000 | -5,861,000 | 725,825,000 | 228,122,000 | 470,667,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-170,975,000
Investing CF
$-19,389,000
Financing CF
$303,862,000
CapEx
$-11,577,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.61
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,457,699,000
Inventory
$25,518,000
Receivables
$133,113,000
ST Investments
$61,352,000
EBIT TTM
$-783,050,000
Pretax Income TTM
$-797,459,000
Interest Exp TTM
$14,409,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$569,609,024
EBITDA
$-50,050,000
Free Cash Flow
$166,895,872
Enterprise Value
$7,724,822,528
Total Cash
$386,259,008
Total Debt
$323,779,008
Shares Out
60,981,227
Trailing EPS
$-13.60
Book Value
$3.98
ROE
-335.8%
ROA
-5.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 521,312,000 | -22,136,000 | -23,363,000 | 842,813,000 | 528,123,000 | — | 55,827,000 |
| Dec 2024 | 336,888,000 | -87,606,000 | -87,942,000 | 670,754,000 | 445,114,000 | — | 10,325,000 |
| Dec 2023 | 186,374,000 | -109,154,000 | -163,415,000 | 646,621,000 | 397,951,000 | — | -70,944,000 |
| Dec 2022 | 77,062,000 | -131,220,000 | -135,665,000 | 352,906,000 | 210,869,000 | — | -120,136,000 |
TTM Snapshot
Revenues TTM
$138,102,000
NetIncome TTM
$-37,823,000
OpCashFlow TTM
$0
Assets (Latest)
$670,754,000
Forward EPS
$-0.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $7.44B | $108.40 | — |
| PTCT | PTC THERAPEUTICS, INC. | $7.04B | $84.85 | — |
| LQDA | Liquidia Corp | $6.93B | $77.93 | — |
| XENE | Xenon Pharmaceuticals Inc. | $6.66B | $68.92 | — |
| COGT | Cogent Biosciences, Inc. | $6.64B | $38.87 | — |
News headlines (Yahoo Finance, 1h cache)
Stocks To Watch: 14 Names Test And Tease New Buy Zones
2026-07-08 20:10 · Yahoo
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib
2026-07-02 09:14 · Yahoo
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
2026-06-29 14:52 · Yahoo
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?
2026-06-25 12:41 · Yahoo
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
2026-06-17 10:47 · Yahoo
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
2026-06-15 14:43 · Yahoo
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
2026-06-14 20:35 · Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-11 20:01 · Yahoo
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?
2026-06-05 15:30 · Yahoo
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
2026-06-04 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.